N-(2-hydroxy-2-methylpropyl)-trimethylacetamide | 110871-47-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-(2-hydroxy-2-methylpropyl)-trimethylacetamide
• 英文别名: N-(2-hydroxy-2-methyl-propyl)-2,2-dimethyl-propionamide；N-(2-hydroxy-2-methylpropyl)-2,2-dimethylpropanamide
• CAS: 110871-47-1
• 化学式: C₉H₁₉NO₂
• 分子量: 173.255
• InChiKey: SXFKFVMXXQDSAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  对氯苯异氰酸酯 、 N-(2-hydroxy-2-methylpropyl)-trimethylacetamide 在 dibutyltin(II) dilaurate 作用下， 以 苯 为溶剂， 反应 14.0h， 以92%的产率得到1,1-dimethyl-2-(2,2-dimethyl-propionyl-amino)-ethyl-N-4-chlorophenyl-carbamate
  参考文献：
  名称：

  Modified tert-butyloxycarbonyl(BOC) derivatives as new aminoprotecting groups

  摘要：

  Some novel low-molecular weight and polymerizable N-acylamino-modified BOC-type aminoprotecting groups are described. Deprotection with trifluoroacetic acid (TFA) and with HBr in acetic acid, which was followed by NMR spectroscopy, leads to the formation of 4,S-dihydro-oxazole derivatives. Reactivities and solubilities of the new compounds are controlled significantly by the N-acyl moiety.

  DOI：

  10.1016/s0040-4020(01)87972-2
• 作为产物：
  描述：

  三甲基乙酰氯 、 1-氨基-2-甲基-2-丙醇 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以89%的产率得到N-(2-hydroxy-2-methylpropyl)-trimethylacetamide
  参考文献：
  名称：

  Modified tert-butyloxycarbonyl(BOC) derivatives as new aminoprotecting groups

  摘要：

  Some novel low-molecular weight and polymerizable N-acylamino-modified BOC-type aminoprotecting groups are described. Deprotection with trifluoroacetic acid (TFA) and with HBr in acetic acid, which was followed by NMR spectroscopy, leads to the formation of 4,S-dihydro-oxazole derivatives. Reactivities and solubilities of the new compounds are controlled significantly by the N-acyl moiety.

  DOI：

  10.1016/s0040-4020(01)87972-2

文献信息

• Homolytic aziridine opening (aza variant of cyclopropylcarbinyl-homoallyl rearrangement) by addition of tributyltin radical to N-acylaziridines. Factors contributing to the regioselectivity
  作者：Jürgen Werrya、Helmut Stamm、Pen-Yuan Lin、Reinhard Falkenstein、Stefan Gries、Hermann Irngartinger

  DOI：10.1016/s0040-4020(01)81081-4

  日期：1989.1

  fell drastically with steric hindrance of the addition of Bu3Sn. to the acyl oxygen of 1. They depended to some extent on the experimental conditions for hydrogen capturing when aziridine homolysis provided a primary radical 3 or 6. The regioselectivity of (probably reversible) ring homolysis can be understood in terms of the stability of the arising radical (3, 6), of stereoelectronic control (e.g. 1i

  AIBN在回流的苯中引发N-酰基丙啶1与Bu 3 SnH的反应，提供了还原性开环的产物5和8。由于添加了Bu 3 Sn的位阻，产率（大多数情况下是定量的）急剧下降。到1的酰基氧。他们在一定程度上取决于当氮丙啶均质分解提供伯自由基3或6时捕获氢的实验条件。的（可能是可逆的）环均裂区域选择性可以的产生自由基（稳定性的观点出发可以理解3，6），立体声电子控制（例如1i与1h相比）和边界轨道相互作用（1j）。从1j形成一级自由基的解释中，键长可能存在差异，但从N-甲苯磺酰基-2-甲基-氮丙啶11的X射线结构分析中未发现支持。异构体产物仅获得两次（1i，1j），比率5j：8j取决于Bu 3 SnH的浓度和氢同位素。没有发现比例为5:14的这种依赖关系（环化和无环化时减少3）由N-肉桂酰基氮丙啶11得到的吡咯烷酮。该比率（1：9为11和1：3为1N）必须反映在EZ异构体3。所观察到的由2形成E-3的偏
• DIPHENYL SUBSTITUTED CYCLOALKANES
  申请人：Ogawa Anthony

  公开号：US20110003815A1

  公开（公告）日：2011-01-06

  The present invention provides compounds of Formula I which are FLAP inhibitors useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

  本发明提供了I式化合物，其为FLAP抑制剂，可用作抗动脉粥样硬化、抗哮喘、抗过敏、抗炎和细胞保护剂。
• Compounds and methods of use
  申请人：Medivation Technologies LLC

  公开号：US10030004B2

  公开（公告）日：2018-07-24

  This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.

  本公开提供了化合物和组合物以及使用这些化合物和组合物治疗与转化生长因子-β（TGFβ）活性过高有关的疾病和失调的方法。本公开还提供了将这些化合物与一种或多种癌症免疫疗法结合使用的方法。
• Pyridazine derivatives as RORc modulators
  申请人：Genentech, Inc.

  公开号：US10487068B2

  公开（公告）日：2019-11-26

  Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, A, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  式 I 的化合物： 或其药用盐、 其中 m、n、A、R1、R2、R3、R4 和 R5 如本文所定义。还公开了制造这些化合物和使用这些化合物治疗炎症性疾病（如关节炎）的方法。
• WERRY, JURGEN;STAMM, HELMUT;LIN, PEN-YUAN;FALKENSTEIN, REINHARD;GRIES, ST+, TETRAHEDRON, 45,(1989) N6, C. 5015-5028
  作者：WERRY, JURGEN、STAMM, HELMUT、LIN, PEN-YUAN、FALKENSTEIN, REINHARD、GRIES, ST+

  DOI：——

  日期：——